Market Cap 1.49B
Revenue (ttm) 235.13M
Net Income (ttm) 5.75M
EPS (ttm) N/A
PE Ratio 22.08
Forward PE 17.48
Profit Margin 2.45%
Debt to Equity Ratio 0.00
Volume 1,451,300
Avg Vol 2,193,402
Day's Range N/A - N/A
Shares Out 131.63M
Stochastic %K 31%
Beta 1.25
Analysts Strong Sell
Price Target $11.71

Company Profile

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement wit...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 744 2487
Fax: 250 708 4345
Address:
#140, 14315 – 118 Avenue, Edmonton, Canada
Perkun
Perkun Oct. 7 at 9:58 AM
$AUPH ☀️
0 · Reply
twakey
twakey Oct. 7 at 7:33 AM
$AUPH Thank you all for your expert views on this company.
0 · Reply
Whpbauer
Whpbauer Oct. 7 at 5:01 AM
$AUPH Sent direct message on his Linkedin page Mr. Tidmarsh, On September 29, you issued a statement that had two provable deceptions regarding voclosporin. In doing so, you have almost certainly caused people with LN to potentially turn away from this proven effective treatment, doctors to now have concern about prescribing this effective treatment and about a $300 million drop in a single company "Aurinia Pharmaceuticals" that has hurt a multitude of investors. You cannot claim this was your personal opinion when you post it on a site that clearly identifies you as the Director for Drug Evaluation and Reasearch, FDA. Voclosporin was approved as an effective treatment for LN by the very agency you work for. You intentionally singled out one company (likely to your dislike of a Board member). This is unacceptable. I believe the only remedy is a sincere public apology and complete public retraction of your declaration that voclosporin has shown no clinical benefit to patients.
0 · Reply
michalinho
michalinho Oct. 7 at 2:57 AM
$AUPH why didnt you sold above 30? Why? Easier to blame others for that? Easier!🎈
0 · Reply
Dameistro
Dameistro Oct. 7 at 1:22 AM
$AUPH bullish harami today, need some volume to push higher to get that bullish crossover from 20ma crossing the 50ma... Close to generating a buy signal then on the way back to recovery.
1 · Reply
therightpicks
therightpicks Oct. 6 at 11:32 PM
$AUPH what a piece of shit stock
1 · Reply
Solomonwisdom7
Solomonwisdom7 Oct. 6 at 9:39 PM
$AUPH The investing community understand there was no credibility to his comments since he pulled it down within hours of posting it. It was noise and the stock will recover based on the value of the amazing safety and efficacy of Lupkynis as well as AUR 200 development
1 · Reply
Hopenitsgood
Hopenitsgood Oct. 6 at 9:33 PM
$AUPH Just look at this chart....for 5 years...FIVE...years..... How on God's green earth is Peter Greenleaf, living it up in the Potomac as CEO of a company with a. "Holy Grail" drug while has done absolutely nothing with regards to ANYTHING positive for patient or investor. Many on both sides have died waiting for the right thing to happen. Peter is sabatoging the company. Day after day, by either doing nothing or doing anything that keeps it dead in the water. Amd im not talking about a climb from previous year. Thats as stupid as biden claiming increase in jobs when its just a climb from a deficit
2 · Reply
Solomonwisdom7
Solomonwisdom7 Oct. 6 at 9:14 PM
$AUPH Based on these projections, Aurinia’s fair value lands at $26.92 per share using the DCF approach. With the current stock price at $11.35, the model suggests the stock is trading at a 57.8% discount to its intrinsic value. This result positions Aurinia as significantly undervalued at today's market levels.
0 · Reply
Solomonwisdom7
Solomonwisdom7 Oct. 6 at 9:12 PM
$AUPH Tidmarsh is no Longer on the attack. He knew he messed up and removed his post.
1 · Reply
Latest News on AUPH
Aurinia Responds to Now Retracted LinkedIn Post

Sep 29, 2025, 8:27 PM EDT - 7 days ago

Aurinia Responds to Now Retracted LinkedIn Post


Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth

Apr 26, 2025, 10:54 AM EDT - 5 months ago

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth


Aurinia Pharmaceuticals: There's Still Time For Sales Growth

Feb 21, 2025, 4:09 PM EST - 8 months ago

Aurinia Pharmaceuticals: There's Still Time For Sales Growth


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 9 months ago

3 Biotech Stocks With Notable Insider Buying

AZN COGT JAZZ ONC XBI ZYME


Aurinia to Participate in Jefferies London Healthcare Conference

Nov 14, 2024, 6:00 AM EST - 11 months ago

Aurinia to Participate in Jefferies London Healthcare Conference


Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon

Nov 8, 2024, 12:15 PM EST - 11 months ago

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon


3 Small Biotech Stocks With The 'Big Mo' Right Now

Sep 19, 2024, 12:54 PM EDT - 1 year ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

CORT VRDN


Aurinia Pharmaceuticals: This Recovery Can Continue

Sep 18, 2024, 4:41 AM EDT - 1 year ago

Aurinia Pharmaceuticals: This Recovery Can Continue


Aurinia Announces Board Restructuring

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Aurinia Announces Board Restructuring


Aurinia Pharmaceuticals Appears Undervalued

Jul 5, 2024, 2:10 PM EDT - 1 year ago

Aurinia Pharmaceuticals Appears Undervalued


Aurinia Announces 2024 Annual General Meeting Results

Jun 14, 2024, 12:16 PM EDT - 1 year ago

Aurinia Announces 2024 Annual General Meeting Results


Perkun
Perkun Oct. 7 at 9:58 AM
$AUPH ☀️
0 · Reply
twakey
twakey Oct. 7 at 7:33 AM
$AUPH Thank you all for your expert views on this company.
0 · Reply
Whpbauer
Whpbauer Oct. 7 at 5:01 AM
$AUPH Sent direct message on his Linkedin page Mr. Tidmarsh, On September 29, you issued a statement that had two provable deceptions regarding voclosporin. In doing so, you have almost certainly caused people with LN to potentially turn away from this proven effective treatment, doctors to now have concern about prescribing this effective treatment and about a $300 million drop in a single company "Aurinia Pharmaceuticals" that has hurt a multitude of investors. You cannot claim this was your personal opinion when you post it on a site that clearly identifies you as the Director for Drug Evaluation and Reasearch, FDA. Voclosporin was approved as an effective treatment for LN by the very agency you work for. You intentionally singled out one company (likely to your dislike of a Board member). This is unacceptable. I believe the only remedy is a sincere public apology and complete public retraction of your declaration that voclosporin has shown no clinical benefit to patients.
0 · Reply
michalinho
michalinho Oct. 7 at 2:57 AM
$AUPH why didnt you sold above 30? Why? Easier to blame others for that? Easier!🎈
0 · Reply
Dameistro
Dameistro Oct. 7 at 1:22 AM
$AUPH bullish harami today, need some volume to push higher to get that bullish crossover from 20ma crossing the 50ma... Close to generating a buy signal then on the way back to recovery.
1 · Reply
therightpicks
therightpicks Oct. 6 at 11:32 PM
$AUPH what a piece of shit stock
1 · Reply
Solomonwisdom7
Solomonwisdom7 Oct. 6 at 9:39 PM
$AUPH The investing community understand there was no credibility to his comments since he pulled it down within hours of posting it. It was noise and the stock will recover based on the value of the amazing safety and efficacy of Lupkynis as well as AUR 200 development
1 · Reply
Hopenitsgood
Hopenitsgood Oct. 6 at 9:33 PM
$AUPH Just look at this chart....for 5 years...FIVE...years..... How on God's green earth is Peter Greenleaf, living it up in the Potomac as CEO of a company with a. "Holy Grail" drug while has done absolutely nothing with regards to ANYTHING positive for patient or investor. Many on both sides have died waiting for the right thing to happen. Peter is sabatoging the company. Day after day, by either doing nothing or doing anything that keeps it dead in the water. Amd im not talking about a climb from previous year. Thats as stupid as biden claiming increase in jobs when its just a climb from a deficit
2 · Reply
Solomonwisdom7
Solomonwisdom7 Oct. 6 at 9:14 PM
$AUPH Based on these projections, Aurinia’s fair value lands at $26.92 per share using the DCF approach. With the current stock price at $11.35, the model suggests the stock is trading at a 57.8% discount to its intrinsic value. This result positions Aurinia as significantly undervalued at today's market levels.
0 · Reply
Solomonwisdom7
Solomonwisdom7 Oct. 6 at 9:12 PM
$AUPH Tidmarsh is no Longer on the attack. He knew he messed up and removed his post.
1 · Reply
3D_STOCK_TRADING
3D_STOCK_TRADING Oct. 6 at 9:04 PM
$AUPH is there news coming with that close?
0 · Reply
guinnessnu
guinnessnu Oct. 6 at 8:42 PM
Wishing for the day $AUPH or $TGTX have a day half as good as $SPRB had today
2 · Reply
Bezhadimmu
Bezhadimmu Oct. 6 at 8:29 PM
$AUPH what a joke. Total horse manure.
0 · Reply
Auphiliate
Auphiliate Oct. 6 at 8:09 PM
$AUPH Can’t recover. Too much water over the dam with poor management and now fda Tidmarsh going on the attack. By far the worst company I ever invested in long term! 🤦‍♀️
2 · Reply
Toni19
Toni19 Oct. 6 at 8:08 PM
$AUPH So, that mean, 50% in the last hour=700k trading shares! https://www.marketwatch.com/investing/stock/auph
0 · Reply
michalinho
michalinho Oct. 6 at 8:05 PM
$AUPH they given a pr. Its tidmarsh's post - not Aurinias MM. Why your diss?
0 · Reply
Dameistro
Dameistro Oct. 6 at 8:04 PM
0 · Reply
ATzmansto
ATzmansto Oct. 6 at 8:03 PM
$AUPH the share price is very tightly controlled. Not sure if the bb is even happening. Our loser management team is not saying or doing anything.
0 · Reply
Yarrow
Yarrow Oct. 6 at 8:00 PM
$AUPH FDA director causes 300 million plummet in MC by posting lies.
2 · Reply
MaryJaneSmokesalot
MaryJaneSmokesalot Oct. 6 at 7:59 PM
$AUPH Red it is Where is that FDA POS Think about how criminal this is He literally could’ve shorted the stock that morning Post his lie Close position and walk away I’m actually not saying that that’s what happened but I’m saying it could’ve happened and he’s facing no legal repercussions Which means that’s a nice dry run for doing it again in the near future
1 · Reply
ScottyK13
ScottyK13 Oct. 6 at 7:12 PM
$AUPH very helpful. Thanks
0 · Reply
Dameistro
Dameistro Oct. 6 at 7:10 PM
$AUPH slow grind upwards... Lookin good
0 · Reply